NCT00250172

PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram

Completed Phase 1 Last updated 16 December 2019

What this trial tests

Phase 1 trial testing [C-11](R)-rolipram in Dosimetry in 26 participants. Completed in 5 February 2009.

Timeline

31 October 2005

Primary endpoint
5 February 2009

5 February 2009

Quick facts

Lead sponsor	National Institute of Mental Health (NIMH)
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Primary purpose	treatment
Enrollment	26
Start date	31 October 2005
Primary completion	5 February 2009
Estimated completion	5 February 2009
Sites	1 location across United States

Drugs / interventions tested

• [C-11](R)-rolipram — full drug profile →

Conditions studied

• Dosimetry — all drugs for Dosimetry →
• Healthy — all drugs for Healthy →

Sponsor

National Institute of Mental Health (NIMH)

Who can join

Adults 18 to 65, any sex, with Dosimetry or Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to measure a particular protein in the brain called the phosphodiesterase by using the imaging techniques of positron emission tomography (PET) and magnetic resonance imaging (MRI).

...

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Clinical Implication of Phosphodiesterase-4-Inhibition.
   Schick MA, Schlegel N. · · 2022 · cited 56× · PMID 35163131 · DOI 10.3390/ijms23031209